Back

Impact of HF etiology on the sustainability of favorable response after LVAD weaning: A VAD Wean Registry analysis

30 August 2024 (13:55 - 14:05)
Organised by: Logo
Congress Presentation Part of: Advanced heart failure: new challenges, new opportunities Ventricular Assist Devices ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Stavros Drakos

University of Utah, Salt Lake City (United States of America)

5 More presentations in this session

Presentation thumbnail
Outcomes of intra-aortic balloon pump in patients with advanced heart failure and cardiogenic shock undergoing heart transplantation
Doctor V. Bellini (Sao Paulo, BR)
Abstract Slides Video
Presentation thumbnail
Reversibility of precapillary pulmonary hypertension and outcomes after heart transplantation bridged with left ventricular assist devices: insight from the UNOS
Doctor H. Alnsasra (Beer Sheva, IL)
Abstract Slides Video
Presentation thumbnail
The hemodynamic classification system for hemodynamic-related adverse events in left ventricular assist device patients
Doctor G. Gallone (Turin, IT)
Abstract Slides Video
Presentation thumbnail
Outflow graft stenosis after left ventricular assist device implantation: the rotterdam experience
Mr P. Jahangiri (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Donor-derived cell-free DNA versus left ventricular global longitudinal strain in noninvasive detection of heart allograft injury
Doctor T. Teszak (Budapest, HU)
Abstract Slides Video

Access the full session

Session thumbnail
Advanced heart failure: new challenges, new opportunities
Video

The Event

Event poster

ESC Congress 2024

30 August 2024 13:55 CET
You may be interested in
thumbnail
Congress Presentation
Impact of HF pharmacological therapy on the durability of favorable response after LVAD weaning: a VAD wean registry analysis
thumbnail
Congress Session
Advanced heart failure: new challenges, new opportunities
thumbnail
Congress Session
Progress in advanced heart failure therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources